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Abstract
Background: Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of
bone and can be primary or secondary, the latter results mainly from the malignant transformation
of a benign pre-existing tumour.
Methods: All the cases diagnosed as Chs (primary tumours, recurrences and/or metastasis and
xenotransplanted Chs) from the files of our Department were collected. Only cases with paraffin
blocks available were selected (Total 32 cases). Six Tissue Microarrays (TMAs) were performed
and all the cases and biopsies were distributed into the following groups: a) only paraffin block
available from primary and/or metastatic tumours (3 TMAs), b) paraffin block available from
primary and/or metastatic tumours as well as from the corresponding Nude mice xenotransplant
(2 TMAs), c) only paraffin block available from xenotransplanted Chs (1 TMA). A reclassification of
all the cases was performed; in addition, conventional hematoxylin-eosin as well as
immunohistochemistry staining (S100, SOX-9, Ki-67, BCL-2, p53, p16, CK, CD99, Survivin and
Caveolin) was analyzed in all the TMA.
Results: The distribution of the cases according to the histopathological pattern and the location
of tumours were as follows: fourteen Grade I Chs (all primaries), two primary Grade II Chs, ten
Grade III Chs (all primaries), five dedifferentiated Chs (four primaries and one primary with
metastasis), and two Chs from cell cultures (Ch grade III). One recurrent extraskeletal myxoid Chs
was included as a control in the TMA. Although there was heterogeneity in immunohistochemistry
results of the different material analyzed, S100, SOX-9, Caveolin and Survivin were more
expressed. The number of passages in xenotransplants fluctuated between 1 and 13. Curiously, in
Grade I Chs, these implanted tumours hardly grew, and the number of passages did not exceed
one.
Conclusion: The study of Chs by means of TMA techniques is very important because it will
improve the assessment of different antibodies applied in the immunohistochemical assays.
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Xenotransplanted tumours in TMA improve knowledge concerning the variability in the
morphological pattern shown by these tumours during the evolution in nudes.
Introduction
The development of Tissue Microarray (TMA) technology
offers the advantage to screening large tissue cohorts for
biomarker expression and to examine serial sections
obtained from the same tumour specimen and xenograft
tumours [1-8]. TMAs are especially suitable for the repro-
duction of morphological and immunohistochemical
(IHC) results in different laboratories [2,4,5]. Chondrosa-
rcoma (Chs) is the third most frequent primary malignant
tumour of bone exceeded only by myeloma and osteosar-
coma. It is characterised by the production of cartilage and
can be primary or secondary, the latter results mainly
from the malignant transformation of benign pre-existing
tumours [9,10]. Several clinical and histopathological
subtypes are recognized and the final diagnoses involve a
large group of physicians including pathologists, radiolo-
gists and surgeons [10-12]. The conventional Chs can be
classified according the location in bone in two groups:
central Chs; located inside the medullar cavity and the
peripheral Chs; located in the surface of the bone [9]. The
histopathology is quite similar in both locations and is
classified in three grades: Grade I, II and III. Grade I Chs
are characterized by cells with small densely straining
nuclei and chondroid or myxoid background, in Grade II
Chs the nucleus are of moderate size with increased cellu-
larity and low mitotic rate, Grade III Chs reveal large
nuclei in areas with increased cellularity with moderate
mitotic rate and scant chondroid or myxoid matrix[9].
Mesenchymal Ch, dedifferentiated Ch and clear cell Ch
are described as infrequent variants of Chs and the clinical
presentation, radiological findings and histopathological
features are different to conventional forms [9-12]. The
differential diagnosis is quite difficult between low grade
Chs and benign chondral conditions, but usually the clin-
ical data, radiography and morphological picture defines
a definitive diagnosis [9,10].
Cytogenetic studies show heterogeneity related to karyo-
typic complexity, nevertheless, alterations in p16 tumour
suppressor gene and p53 are related with Ch progression
[9,10,13,14].
Xenograft models in bone tumour are of great importance
because nude tumours constitute an easy source of mate-
rial for tumour characterization using histopathological,
IHC, electron microscopy, cytogenetic and molecular
biology criteria [6,7,15]. Usually the histology of the
tumours is preserved and they can also be followed over
subsequent generations in various tumours passages
[7,15]. Xenograft models in Chs are performed infre-
quently and being followed for successive generations is
even more sporadic. Few publications exist on TMA study
in Chs and the combination with a xenograft study is even
more unusual. Therefore, the aims of this study are firstly
the analysis of heterogeneity in Chondrosarcomas by
means of TMA technology using histopathological and
IHC criteria and secondly to analyze their successive
xenografts after xenotransplantation into nude mice fol-
lowed for several passages to describe the histopathologi-
cal and IHC pattern variations occurring in the original
tumour and their successive xenotransplants.
Materials and methods
Samples sources
All the cases diagnosed as Chs (primary tumours, recur-
rences and/or metastasis and xenotransplanted Chs) from
the files of our Department were collected. Only cases
with paraffin blocks available were selected. All the clini-
cal data of the patients were reviewed. (Total: 32 cases). A
reclassification of all the cases according to the new crite-
ria for Chs diagnosis (WHO) was performed.
Assembly of TMA
Six TMAs were performed and all the cases and biopsies
were distributed into the following groups: a) only paraf-
fin block available from primary and/or metastatic
tumours (3 TMA), b) paraffin block available from pri-
mary and/or metastatic tumours as well as from the corre-
sponding Nude mice xenotransplant (2 TMA), c) only
paraffin block available from xenotransplanted Chs (1
TMA). A hematoxylin and eosin stained (H/E) section
from each primary tumour and xenograft was prepared
and areas of representative non-necrotic neoplasm circled
on coverslip. The TMAs were assembled using a manual
tissue arrayer (Beecher Instruments, Sun Prairie, WI). Nor-
mally, two cores (1 mm in thickness) of each biopsy were
performed; nevertheless, more than 2 cores were made if
the biopsy revealed a different pattern. All TMAs included
two cores of normal kidney or liver as control tissues. Fol-
lowing TMA construction, H/E stained section of the TMA
recipient block was prepared and reviewed to confirm the
presence of intact neoplasm. Several sections of 5 μ were
prepared in order to perform H/E stain as well as different
IHC staining.
Immunohistochemical analysis
IHC analysis was performed using anti-CD99 antibody
(clone 12E7, DakoCytomation) at a 1:50 dilution, anti-
S100 polyclonal antibody (DakoCytomation) at a 1:200
dilution, anti-SOX-9 polyclonal antibody (Santa CruzDiagnostic Pathology 2008, 3:S25 http://www.diagnosticpathology.org/content/3/S1/S25
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Biotechnology, Santa Cruz, CA) at 1:100 dilution, anti-
survivin polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) at 1: 50 dilution, anti-p16 antibody
(clone F12, Santa Cruz Biotechnology, Santa Cruz, CA) at
1:100 dilution, anti-p53 antibody (clone DO7, Novocas-
tra) at 1:50 dilution, pan-CK (AE1/AE3) antibody (Dako-
Cytomation) at 1:50 dilution, anti-Ki-67 antibody (MIB-
1, DakoCytomation) at 1:50 dilution, anti-Caveolin
(CAV) polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) at 1:200 dilution, anti-Bcl-2 antibody
(clone 124, Novocastra) at 1:50 dilution. Antigen retrieval
was performed by pressure cooker boiling for 3 minutes in
10 mmol/L of citrate buffer (pH 6.0). The LSAB method
(DakoCytomation) was used, followed by revelation with
3,3'-diaminobenzidine. Cytoplasmic and/or membrane
staining was considered positive for CD99, S100, CK, CAV
and Bcl-2 antibodies, nuclear staining was considered
positive for SOX-9, Survivin, p53, p16 and Ki-67 antibod-
ies. Sections were examined and immunoreactivity was
defined as follow: negative, fewer than 5% of tumour cells
stained; poorly positive (+), 5% to 10% of tumours cells
stained; moderately positive (++), 10% to 50% of
tumours cells stained and strongly positive (+++), more
than 50% of the tumours cells were stained. All sections
were evaluated independently by 3 pathologists (IM, SN
and ALLB). The agreement of staining intensity scoring by
all was recorded, and in cases of disagreement, intensity
and score was determined by consensus.
Xenotransplant
Male nude mice, were purchase from IFFA-CREDO (Lyon,
France), kept under specific pathogen-free conditions
throughout the experiment, and provided with vinyl iso-
lates plus sterilized food, water, cage and bedding. The
specimens for xenotransplant were obtained at surgery
(OT) and placed in a culture medium (RPMI 1640) plus
antibiotic at 37  until transplantation, usually 6 hours
after surgery. Fragments of non-necrotic tumour, about 3
to 5 mm in size, were transplanted into the subcutaneous
tissue in the backs of two nude mice. The new tumour
transfers were made by following the same procedure as in
the initial xenotransplant and always under highly sterile
conditions. Material from different passages was obtained
in order to perform all TMAs. Additional material was
obtained for electron microscopy, culture, and frozen sec-
tions.
Results
Grade I and Grade III Chs were the most frequent his-
topathological patterns, the distribution of the cases were
as follows: fourteen Grade I Chs (all primaries), two pri-
mary Grade II Chs, ten Grade III Chs (all primaries) (Fig-
ure 1), five dedifferentiated Chs (four primaries and one
primary with metastasis) and two Chs from cell cultures
(Ch grade III). One recurrent extraskeletal myxoid Chs
was included as a control in the TMA. Most of the tumours
were located in bone and/or soft tissue. The results of IHC
study are given in Table 1. Although there was heterogene-
ity in IHC results of the different material analyzed, S100,
SOX-9, Caveolin and Survivin were more expressed (Fig-
ure 1).
Concerning xenografts, the number of passages in
xenotransplants fluctuated between 1 and 13. Curiously,
in low grade – Grade I Chs, these implanted tumours
hardly grew, and the number of passages did not exceed
one. Nevertheless, in Grade II or Grade III Chs the number
of passages were greater. An example of dedifferentiated
Chs evolution in nudes is described in Table 2 and (Fig-
ures: 2, 3, 4, 5, 6).
Discussion
TMA-based morphological and IHC evaluation of Chs pri-
mary tumour and xenograft proved to be a high through-
put source in demonstrating the phenotypic variability of
original and xenograft Chs. Grading Chs has proven prog-
nostic value, nevertheless the differential diagnosis
between low grade Chs and benign chondroid lesions is
quite difficult and requires an integration of clinical, radi-
ology and histopathology information [9-12]. Grade I Ch
was the most frequent in this cohort, as reported in the lit-
erature and most of the tumours appeared in bone and
Table 1: Inmunohistochemical profile. N/A = Not assessable
Antibodies N/A Negative (-) Poorly positive (+) Moderately positive (++) Strongly positive (+++)
S100 30 0 1 2 8
SOX-9 12 7 5 1 7
Survivin 22 4 3 2 1
Caveolin 11 6 1 2 1 2
CD99 28 1 2 5 5
p16 51 0 8 3 6
p53 21 6 6 6 2
Ki-67 47 5 9 7
Bcl-2 31 6 7 3 3
CK 12 8 2 1 0Diagnostic Pathology 2008, 3:S25 http://www.diagnosticpathology.org/content/3/S1/S25
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soft tissue [16]. At the histopathological level, the distinc-
tion between Grade I, II, III and dedifferentiated Chs was
relatively easy using the updated criteria described [9,10].
S100 immunoreactivity in chondroid foci and the tran-
scription factor SOX-9 (regulator of chondrogenesis) has
been reported as the most sensitive and confirmatory
markers in Chs diagnosis, both were the most expressed in
the study. SOX-9 staining differentiates Chs from various
small cells round tumour such as small cell osteosarco-
mas, non-Hodgkin lymphomas and Ewing/PNET family
tumours [17]. Recently, the expression of Bcl-2 and par-
athyroid-like hormone (PTHLH) as two antibodies that
supported Ch diagnosis and differentiating them from
other benign conditions as osteochondromas has been
described [18], although in the present study, Bcl-2
expression was infrequent in the original tumours and in
their corresponding xenograft. Curiously, CAV and Sur-
vivin were overexpressed in Chs, therefore apoptosis and
cell interactions could be related to tumour chondrogene-
sis. Further studies with larger series could provide new
insight into the pathogenesis of Chs.
Xenograft materials are widely used by researchers
although in the case of Chs tumours; few studies have
been published using TMA technology [19]. As many Chs
tumours reveal different patterns in the same biopsy, it is
not surprising that the xenograft tumour showed different
histopathological pictures in some cases compared with
the original tumour. Usually, Grade I Chs showed no var-
iation in histology and IHC between the primary tumours
and their xenograft. Intriguingly, in Grade I Chs, these
implanted tumours hardly grew, and the number of pas-
sages did not exceed one, whereas in Grade III; dedifferen-
tiated Chs as well as in Chs from culture, the numbers of
successive passages were higher, and light microscopy as
well as IHC study revealed differences between primary
tumour and their xenograft. Tumour cells in Chs culture
could acquire newer genetic and/or epigenetic alterations
Dedifferentiated Ch, Original Tumour Figure 2
Dedifferentiated Ch, Original Tumour.
Table 2: Model of Xenograft in Ch. Evolution in Nude mice
Material De-differentiation S100 SOX-9 Ki-67 p53
Original Tumour + ++ +++ + +
Nu385-P0 ++ ++ ++ ++ ++
Nu385-P1 +++ + + ++ +++
Nu385-P2 +++ + + +++ +++
Nu385-P3 +++ Osteoid + + +++ +++
Histopathology and IHC profile in Chs Figure 1
Histopathology and IHC profile in Chs.Diagnostic Pathology 2008, 3:S25 http://www.diagnosticpathology.org/content/3/S1/S25
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that increase the aggressive phenotype; in addition, these
cells in culture grow quite fast and replace stromal and
necrotic cells from the original tumour. Original tumours
(Grade III or dedifferentiated Ch) developed morpholog-
ical transformation to a poorly differentiated subtype in
some of the successive xenotransplanted tumours, in
addition differences between IHC expression of chondro-
genic differentiation markers (S100, SOX-9), cell cycle
regulators (p53, p16) and proliferation marker (Ki-67)
were detected. The dedifferentiated Ch xenograft model
displayed a morphological transition over subsequent
passages in nude mice, initially the tumour showed a
biphasic pattern characterized by areas with typical chon-
droblastic differentiation surrounding by areas with
marked dedifferentiation. Over the successive passages,
the tumour acquired more dedifferentiation and the last
tumours passages revealed osteoid material similar to
osteosarcoma. The approximate period between passages
was three months. In addition, S100 and SOX-9 expres-
sion showed relatively decreased expression and Ki-67,
p53 and p16 revealed increased expression in the succes-
sive xenograft. Some of these changes may represent
newer genetic and/or epigenetic alterations developed in
more aggressive subclones or could be induced by the
establishment of the xenograft as occurs in tumour pro-
gression[6,7]. TMAs in xenografted tumours offer an
invaluable tool for performing further research in order to
study newer markers of cell differentiation, activation,
genetics and cell signalling in Chs. Despite the increasing
use of TMAs, limitations remain, particularly in the case of
tumours, due to intratumoral heterogeneity of protein
expression [1,5]. Therefore in order to ensure TMA repre-
sentativeness, more representative areas of sections of the
original donor block should be selected, as well as increas-
ing the number of cores collected and the size of the single
cores [5]. Nowadays, TMAs are becoming an indispensa-
ble tool in the study of cancer progression and provide
newer insights concerning the biology of several tumours.
Conclusion
The analysis in TMA of Chs xenograft followed for succes-
sive generations provides new information concerning the
biology and morphology of these tumours. The histopa-
thology remained similar to the original tumour in most
of the cases, but occasionally, as in the model displayed,
the tumours acquire more dedifferentiation after several
Nude 385 Passage 1 Figure 4
Nude 385 Passage 1.
Nude 385 Passage 0 Figure 3
Nude 385 Passage 0.Diagnostic Pathology 2008, 3:S25 http://www.diagnosticpathology.org/content/3/S1/S25
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transfer. IHC studies using TMA techniques are useful for
the assessment of the antibodies related to Chs.
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